Symposium: The Role Of Interferon In Metastasis And Resistance To DNA Damage In Prostate Cancer

The Glickman Urological & Kidney Institute, Lerner Research Institute, and Case Comprehensive Cancer Center invite you to attend a symposium on "The Role Of Interferon In Metastasis And Resistance To DNA Damage In Prostate Cancer" on February 7, 2013 at Room Q1-300, Glickman Institute, Cleveland Clinic.

Registration

Save the date. The capacity of the meeting room is limited. To secure your place, please register through the online form below:

First Name:
Last Name:
Email Address:

Program:

8:30 am

George Stark, Cleveland Clinic

Introduction and welcome

8:40 am

Andrei Gudkov, Roswell Park  Cancer Institute

“p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of non-coding RNAs”

9:20 am

George Stark and HyeonJoo Cheon, Cleveland Clinic

“A sustained response to interferon beta is mediated by unphosphorylated ISGF3 (U-ISGF3)”

10:00 am

Ralph Weichselbaum and Nikolai Khodarev, University of Chicago

“The U-ISGF3 signature and resistance to DNA damage in cancer”

10:40 am

Coffee break

11:20 am

Robert Silverman, Cleveland Clinic

“The interferon-induced 2-5A system and prostate cancer”

12:00 pm

Mark Jackson, Case Western Reserve University

“The roles of interferons in EMT and metastasis”

12:40 pm

Lunch

1:40 pm

Stefan Ambs, National Cancer Institute, NIH

“A distinct immune signature in prostate tumors of African American men”

2:20 pm

Eric Klein and Andrew Stephenson, Cleveland Clinic

“Use of gene expression profiles of prostate biopsies to predict disease aggressiveness”

3:00 pm

All speakers

Conclusion and Summary